Epigenetic Reprogramming Drug Pipeline — PatSnap Eureka
Epigenetic Reprogramming Drug Pipeline: OSK Factors & Partial Reprogramming in Aging
Aging-driven organ decline is increasingly understood as a reversible epigenetic process. OSK and OSKM partial reprogramming approaches are catalyzing a new class of interventions targeting DNA methylation, PRC2, and HDAC pathways across pancreas, retina, liver, kidney, and beyond.
Aging as a Reversible Epigenetic Program
Research converges on a central thesis: aging represents the progressive, tissue-wide accumulation of epigenetic errors that disrupt normal gene regulatory programs, ultimately producing functional decline across the pancreas, liver, spleen, blood, skin, retina, kidney, intervertebral disc, and musculoskeletal system. The primary molecular targets include stereotyped hypermethylation and hypomethylation at specific CpG loci.
IRB Barcelona demonstrated that transient OSKM expression reverses DNA methylation changes across pancreas, liver, spleen, and blood in naturally aged mice. PatSnap's life sciences intelligence platform tracks this growing body of IP and literature in real time. Altos Labs research identifies a striking convergence of age- and rejuvenation-related DNA methylation changes at targets of the Polycomb Repressive Complex 2 (PRC2), positioning this chromatin regulatory complex as a key mediator of tissue aging.
The epigenetic clock (Horvath-type DNA methylation age) functions as both a biomarker and a therapeutic readout across multiple retrieved results, serving as the primary quantitative endpoint for rejuvenation efficacy. According to WHO, age-related diseases represent a growing global health burden, making these mechanistic insights particularly urgent.
A novel target outside the canonical Yamanaka framework, SRSF1 (serine/arginine-rich splicing factor 1), was identified by the Wyss Institute at Harvard via transcriptomic screening—demonstrating that the rejuvenation target space extends well beyond OSK/OSKM. Meanwhile, HDAC1/2 inhibition via Compound 60 (Cmpd60) produces organ-level transcriptional mimicry of multiple longevity genetic interventions in naturally aged mice.
Six Approaches to Partial Epigenetic Reprogramming
From mRNA delivery and viral gene therapy to small molecules and maturation-phase transient reprogramming—each modality addresses distinct translational challenges in aging biology.
Transient mRNA-Based Reprogramming
Two patents assigned to The Board of Trustees of the Leland Stanford Junior University describe compositions and methods for rejuvenating aged cells via transient, non-integrated mRNA encoding reprogramming factors, retaining differentiated cell identity. Brief, episodic mRNA transfection induces partial epigenetic resetting without completing the iPSC trajectory. Stanford papers show effects persisting four to six days post-interruption, with broad amelioration of aging hallmarks in human fibroblasts and endothelial cells within two days of treatment.
Preclinical / IND-enabling · Human cell & mouse in vivo dataViral Gene Therapy–Mediated AAV-OSK
Systemically delivered AAVs encoding an inducible OSK system, administered to 124-week-old mice, extended median remaining lifespan by 109% over wild-type controls and improved multiple health parameters. Doxycycline-inducible expression controls the duration of reprogramming factor expression in vivo, addressing oncogenic risk of sustained OSKM activity. The Harvard Medical School OSK retinal study uses viral delivery to the eye as a clear organ-specific in vivo proof-of-concept.
Preclinical in vivo · Aged wild-type miceCyclic OSKM Expression in Transgenic Models
INSERM/Montpellier group data show that a single 2.5-week OSKM induction early in life improves body composition, functional capacity, and tissue structure (kidney, spleen, skin, lung) throughout the lifespan, with a 15% increase in lifespan. Lausanne University Hospital identifies a critical safety boundary: continuous (non-cyclical) in vivo OSKM expression causes hepatic and intestinal failure and premature death, underscoring that temporal control is mechanistically essential.
Preclinical in vivo · Transgenic mouse modelsChemical / Small Molecule Partial Reprogramming
University of Lausanne demonstrated that partial chemical reprogramming using small molecule cocktails can reverse key aging hallmarks—genomic instability, epigenetic alterations—in aged human cells, and that an optimized two-molecule combination is sufficient to induce broad aging phenotype amelioration. Amsterdam University Medical Centers identifies Compound 60 (Cmpd60), a selective HDAC1/2 inhibitor, as capable of rejuvenating multiple organ systems in aged mice based on transcriptome-mimicry of longevity-associated genetic interventions. PatSnap's chemical intelligence tools can map HDAC inhibitor IP landscapes.
Preclinical · In vitro human cells & in vivo aged miceMaturation Phase Transient Reprogramming (MPTR)
Babraham Institute introduces MPTR, a refinement in which reprogramming factors are expressed only until the maturation phase (before full dedifferentiation), then withdrawn. Applied to dermal fibroblasts from middle-aged donors, MPTR achieved multi-omic rejuvenation—epigenomic, transcriptomic—while cells temporarily lost but subsequently reacquired fibroblast identity. This approach reduces the window of cell identity loss compared with conventional cyclic reprogramming.
Preclinical · Human cell in vitro (middle-aged donors)RNA-Based Non-Integrating Delivery Platforms
SAFE-iPSC/Montpellier group highlights mRNA, self-amplifying RNA, and circular RNA platforms as non-integrating, non-genotoxic delivery vehicles for reprogramming factors with potential healthspan applications. This modality is directly aligned with the Stanford patents and addresses the translatability gap created by viral and transgenic approaches. According to NIH, non-integrating RNA delivery is a priority area for gene therapy safety research.
Preclinical · Platform stagePipeline Signals: Targets, Modalities & Evidence Density
Derived from patent and literature analysis of 24 source records spanning 2018–2023 via PatSnap Eureka.
Therapeutic Modalities by Evidence Density
mRNA delivery and AAV-OSK carry the highest combined patent and paper evidence weight in this dataset.
Molecular Target Categories in Dataset
Transcription factors (OSK/OSKM) dominate, with chromatin regulators and small-molecule targets comprising the remainder.
In Vivo Efficacy Highlights from Key Studies
AAV-OSK systemic delivery in 124-week-old mice produced the largest lifespan extension signal in this dataset.
Organ Systems Targeted Across Retrieved Studies
Retina and CNS are identified as leading candidates for first-in-human studies due to immune-privileged status and accessible delivery routes.
Key Targets, Mechanisms & Lead Organizations
Derived from 24 patent and paper records. All claims traceable to source dataset.
| Target | Mechanism | Key Finding | Lead Organization | Modality |
|---|---|---|---|---|
| OSK (OCT4, SOX2, KLF4) | Transient pluripotency factor expression; DNA methylation clock reversal | 109% median lifespan extension in 124-week-old mice via AAV-OSK; vision restoration in aged retina | Harvard Medical School; Stanford | AAV Gene Therapy |
| OSKM (+ c-MYC) | Full Yamanaka factor set; broader epigenetic resetting | Single 2.5-week induction improves body composition, tissue structure, 15% lifespan increase; continuous expression causes hepatic/intestinal failure | INSERM/Montpellier; Lausanne University Hospital | Transgenic / Dox-inducible |
| PRC2 (Polycomb Repressive Complex 2) | Chromatin regulator; dominant convergence point for aging drift and reprogramming-mediated rejuvenation | Whole-genome bisulfite sequencing identifies PRC2 target loci as central to both aging epigenetic drift and OSK rejuvenation in mouse skin | Altos Labs | Small Molecule Target |
| HDAC1/2 | Histone deacetylase inhibition; transcriptome-level mimicry of longevity interventions | Compound 60 (Cmpd60) rejuvenates multiple organ systems in aged mice, mimicking transcriptional profiles of multiple genetic longevity interventions | Amsterdam University Medical Centers | Small Molecule |
| SRSF1 | Serine/arginine splicing factor; non-Yamanaka rejuvenation factor | Overexpression shifts cell transcriptomes toward younger state; improves cellular function in vitro and in vivo | Wyss Institute, Harvard | cDNA / Gene Expression |
| DNMT / TET enzymes | DNA methylation writers and erasers; epigenetic barrier modulation | Two-molecule chemical combination sufficient for broad aging phenotype amelioration in human cells; TET1/2 co-operation accelerates reprogramming efficiency | University of Lausanne; Emory University | Small Molecule |
| ZEB2 / Zeb2-NAT lncRNA | Age-elevated ZEB2 constitutes reprogramming barrier; LNA Gapmer silencing restores competence | Silencing Zeb2-NAT restores reprogramming competence in aged fibroblasts | University of Lisbon | LNA Gapmer / RNA Silencing |
Monitor Continuation Filings & Freedom-to-Operate Signals
Stanford's mRNA reprogramming patents (IL & SG) are foundational. Track new claims with PatSnap Analytics.
Five Emerging Strategic Directions in Partial Reprogramming
Retrieved results signal combination strategies that may overcome the limitations of single-modality approaches.
Small Molecules + Yamanaka Factors
Lausanne University data shows that combining small molecules with Yamanaka factors in an ERCC1 premature aging model achieves potent DNA damage reversion and upregulation of mitotic fidelity pathways. Chemical agents lower the epigenetic barrier while transcription factors provide directional resetting.
PRC2 Modulation as Small-Molecule Route
Altos Labs convergence data suggests PRC2 modulation may be a pharmacologically tractable route to enhance or mimic partial reprogramming outcomes, potentially enabling small molecule–only approaches targeting this complex without gene delivery requirements.
SRSF1 as Non-Yamanaka Rejuvenation Factor
The Wyss Institute SRSF1 discovery signals that transcriptomic screening approaches are identifying rejuvenation factors outside the canonical OSK/OSKM framework, opening a broader target space. This may lead to screens combining SRSF1 overexpression with other factors or small molecules.
Senolytic + Partial Reprogramming Combinations
Heidelberg University conceptualizes synergistic anti-aging through senescent cell–specific reprogramming. Weizmann Institute data shows that rejuvenation strategies—including partial reprogramming, senolytics, caloric restriction, and young blood factor exchange—share a common gene expression program: reduced inflammation upstream of restored fatty acid metabolism.
Strategic Patent & Publication Landscape
In this dataset, innovation activity spans a mix of academic institutions, corporate laboratories, and one major biotech. The IP landscape is sparsely but strategically populated: The Board of Trustees of the Leland Stanford Junior University holds the foundational mRNA-based reprogramming composition patents across multiple jurisdictions (IL, SG), while the bulk of mechanistic and in vivo efficacy data resides in academic publications. Drug developers should monitor continuation filings and freedom-to-operate exposure in non-integrating RNA delivery for cellular rejuvenation.
Altos Labs (San Diego) is represented by a 2023 whole-genome methylation profiling paper identifying PRC2 as a central epigenetic mediator—signaling significant corporate investment in understanding mechanistic determinants of rejuvenation. The European Patent Office and global patent databases accessible via PatSnap provide comprehensive coverage of continuation filings in this space.
Activity in this dataset is predominantly literature-driven (academic papers), with patent filings concentrated at Stanford. This suggests the commercial translation layer is at an early but strategically protected stage. Developers building programs on OSK or OSKM should assess freedom-to-operate relative to Stanford's IL and SG filings, and monitor for US and EU continuation applications.
For enterprise IP teams managing competitive intelligence in aging biology, PatSnap customer case studies demonstrate how leading life sciences organizations track emerging reprogramming IP in real time. The PatSnap API also enables programmatic access to patent landscapes for integration into R&D workflows.
Preclinical-to-Clinical Translation Indicators
No completed clinical trials or regulatory submissions are documented in retrieved results. However, multiple translational signals are present across the dataset.
Stanford mRNA Patents: Clinical Platform Alignment
Stanford patents (IL and SG jurisdictions, pending as of 2020) describe compositions explicitly framed for "tissue engineering and regenerative medicine," with human cell data from fibroblasts and endothelial cells from "human clinical samples" supporting IND-enabling studies. The use of mRNA delivery—a clinically validated platform—substantially reduces translational distance compared with viral or transgenic approaches. According to FDA guidance, mRNA-based therapeutics have established regulatory pathways.
mRNA · Human cell validation · IL & SG jurisdictionsMulti-Center Human Cell Validation
Multiple papers demonstrate that transient reprogramming reverses aging hallmarks in human (not only murine) cells—including fibroblasts from aged donors (Stanford; Babraham MPTR; University of Lausanne chemical reprogramming). This cross-center human cell validation is a prerequisite for clinical translation and strengthens the biological rationale for IND applications.
Stanford · Babraham · Lausanne · Human aged donor fibroblastsAAV-OSK: 109% Median Lifespan Extension in Aged Mice
Systemic AAV-OSK in 124-week-old mice extended median remaining lifespan by 109% over wild-type controls and improved multiple health parameters. This represents among the strongest in vivo aging reversal data in this dataset, establishing a compelling preclinical proof-of-concept for systemic partial reprogramming—though in mice only, with no human data yet reported.
124-week-old mice · Systemic AAV · Doxycycline-inducibleCmpd60 HDAC1/2 Inhibitor: Multi-Organ Rejuvenation
Compound 60 (Cmpd60), described as mimicking transcriptional profiles of genetic longevity interventions in aged mice across multiple organ systems, positions HDAC1/2 inhibition as the most direct pharmacological translation path in this dataset. The small-molecule nature avoids gene delivery complexities and has a more established regulatory precedent. PatSnap's trust center provides data provenance for all IP records used in drug development decisions.
Small molecule · Multi-organ · Amsterdam UMCThis report is derived from a limited set of patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline, regulatory landscape, or complete academic literature. No clinical trial data, patient cohort studies, or IND filings are explicitly documented in retrieved results.
Epigenetic Reprogramming in Aging — Key Questions Answered
Partial reprogramming involves transient, episodic expression of pluripotency transcription factors (such as OSK or OSKM) that induces epigenetic resetting without completing the full iPSC trajectory. Unlike full reprogramming, cells temporarily lose but subsequently reacquire their differentiated identity, retaining cell function while reversing aging hallmarks. The Babraham Institute's MPTR methodology expresses reprogramming factors only until the maturation phase, before full dedifferentiation, then withdraws them.
OSK (OCT4, SOX2, KLF4) omits c-MYC, which is associated with oncogenic risk. Multiple research groups converge on OSK as providing rejuvenating efficacy with reduced oncogenic liability compared with full OSKM, a distinction critical for IND strategies in non-dividing post-mitotic tissues such as retina and neurons. The Harvard Medical School OSK retinal study demonstrated DNA methylation clock reversal and functional vision restoration using OSK without c-MYC.
Retrieved results cover pancreas, liver, spleen, blood, skin, retina, kidney, intervertebral disc, and musculoskeletal system. The Harvard Medical School OSK study focused on retinal ganglion cells and optic nerve. INSERM/Montpellier OSKM induction improved kidney, spleen, skin, and lung tissue structure. Amsterdam University Medical Centers' Cmpd60 HDAC1/2 inhibitor rejuvenated multiple organ systems in aged mice.
Lausanne University Hospital data shows that continuous (non-cyclical) in vivo OSKM expression causes hepatic and intestinal failure and premature death, underscoring that temporal control is mechanistically essential. Any systemic in vivo reprogramming program must incorporate tissue-selective expression systems, such as tissue-specific promoters or organ-sparing AAV serotypes. The oncogenic risk of c-MYC is a further safety consideration addressed by using OSK instead of OSKM.
PRC2 (Polycomb Repressive Complex 2) and HDAC1/2 are identified as the most actionable small-molecule targets in this dataset. Altos Labs' PRC2 convergence data and the Amsterdam HDAC1/2 inhibitor Cmpd60 multi-organ rejuvenation results represent the clearest small-molecule entry points for epigenetic reprogramming-inspired drug development without requiring gene delivery. DNMT inhibitors and TET enzyme activators are also described as components of chemical reprogramming cocktails.
In this dataset, The Board of Trustees of the Leland Stanford Junior University holds the foundational patent filings covering mRNA-based transient reprogramming compositions for cellular rejuvenation, filed in IL and SG jurisdictions (both pending as of 2020). The bulk of mechanistic and in vivo efficacy data resides in academic publications from Altos Labs, Harvard Medical School, Wyss Institute, INSERM/Montpellier, IRB Barcelona, Babraham Institute, University of Lausanne, and Amsterdam University Medical Centers.
Still have questions about epigenetic reprogramming targets or pipeline data? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About ReprogrammingAccelerate Your Epigenetic Reprogramming Drug Discovery
Join 18,000+ innovators already using PatSnap Eureka to map aging biology IP, identify actionable targets, and monitor pipeline signals across OSK, PRC2, HDAC, and beyond.
References
- Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming — IRB Barcelona, 2022
- Multi-omic rejuvenation of naturally aged tissues by a single cycle of transient reprogramming — Centre de Recherche des Cordeliers / Sorbonne Université, 2022
- Convergence of aging- and rejuvenation-related epigenetic alterations on PRC2 targets — Altos Labs, 2023
- Gene Therapy Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice — 2023
- Reversal of ageing- and injury-induced vision loss by Tet-dependent epigenetic reprogramming — Harvard Medical School, 2019
- Transcriptomic reprogramming screen identifies SRSF1 as rejuvenation factor — Wyss Institute, Harvard, 2023
- Treatment with a selective histone deacetylase (HDAC) 1 and 2 inhibitor in aged mice rejuvenates multiple organ systems — Amsterdam University Medical Centers, 2023
- Transient cellular reprogramming for reversal of cell aging — Stanford University (Patent, IL jurisdiction), 2020
- Transient cellular reprogramming for reversal of cell aging — Stanford University (Patent, SG jurisdiction), 2020
- Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells — Stanford University, 2020
- Transient non-integrative nuclear reprogramming promotes multifaceted reversal of aging in human cells — VA Palo Alto / Stanford, 2019
- A single short reprogramming early in life improves fitness and increases lifespan in old age — IRMB / INSERM Montpellier, 2021
- A single short reprogramming early in life initiates and propagates an epigenetically related mechanism improving fitness — SAFE-iPSC Facility, CHU Montpellier, 2022
- In vivo reprogramming leads to premature death due to hepatic and intestinal failure — Lausanne University Hospital, 2022
- Chemical reprogramming ameliorates cellular hallmarks of aging and extends lifespan — University of Lausanne, 2022
- Initiation phase cellular reprogramming ameliorates DNA damage in the ERCC1 mouse model of premature aging — University of Lausanne, 2023
- Small Molecule Epigenetic Modulators in Pure Chemical Cell Fate Conversion — Sun Yat-sen University, 2020
- Multi-omic rejuvenation of human cells by maturation phase transient reprogramming — Babraham Institute, 2022
- Multi-omic rejuvenation of human cells by maturation phase transient reprogramming — Babraham Institute, 2021
- RNA-Based Strategies for Cell Reprogramming toward Pluripotency — SAFE-iPSC Facility, CHU Montpellier, 2022
- Coordination of Engineered Factors with TET1/2 Promotes Early-Stage Epigenetic Modification — Emory University, 2014
- Silencing of the lncRNA Zeb2-NAT facilitates reprogramming of aged fibroblasts — University of Lisbon, 2018
- Synergistic Anti-Ageing through Senescent Cells Specific Reprogramming — Heidelberg University, 2022
- Rejuvenation strategies share gene expression programs of reduced inflammation and downstream restored fatty acid metabolism — Weizmann Institute of Science, 2022
- World Health Organization (WHO) — Ageing and Health
- National Institutes of Health (NIH) — RNA Therapeutics Research
- U.S. Food and Drug Administration (FDA) — mRNA Therapeutic Guidance
- European Patent Office (EPO) — Biotechnology Patent Database
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline, regulatory landscape, or complete academic literature.
PatSnap Eureka searches patents and research to answer instantly.